Publications by authors named "M J Person"

Thirty-four per cent of deaths among Americans aged 1-46 are due to injury, and many of these deaths could be prevented if all hospitals performed as well as the highest-performing hospitals. The Institute of Medicine and the National Academies of Science, Engineering and Medicine have called for learning health systems, with emphasis on clinical practice guidelines (CPGs) as a means of limiting preventable deaths. Reduction in mortality has been demonstrated when evidence-based trauma CPGs are adhered to; however, guidelines are variably updated, redundant, absent, inaccessible, or perceived as irrelevant.

View Article and Find Full Text PDF

Background: Alzheimer's disease is the most common type of dementia and is responsible for up to 80% of dementia diagnoses and is the sixth leading cause of death in the United States. An estimated 38,000 American Indian/Alaska Native (AI/AN) people aged ≥65 years were living with Alzheimer's disease and related dementias (ADRD) in 2020, a number expected to double by 2030 and quadruple by 2050. Administrative healthcare data from the Indian Health Service (IHS) were used to estimate ADRD among AI/AN populations.

View Article and Find Full Text PDF
Article Synopsis
  • Neuroinflammation may impact brain integrity in both multiple sclerosis (MS) and major depressive disorder (MDD), yet the relationship between imaging markers and neuroinflammatory activity needs further exploration.
  • A study involving 684 participants used advanced MRI to analyze gray-to-white matter contrast (GWc) and revealed that both MS and MDD patients exhibited significant changes in brain connectivity compared to healthy controls.
  • The findings indicated that abnormalities in GWc were linked to increased depressive symptoms across different groups, suggesting shared inflammatory mechanisms between MDD and MS that could influence treatment approaches.
View Article and Find Full Text PDF

Involving diverse populations in early-phase (phase I and II) cancer clinical trials is critical to informed therapeutic development. However, given the growing costs and complexities of early-phase trials, trial activation and enrollment barriers may be greatest for these studies at healthcare facilities that provide care to the most diverse patient groups, including those in historically underserved communities (e.g.

View Article and Find Full Text PDF